ArticleBMC medical imaging2025
Radiomic imaging models for predicting breast cancer prognosis based on Interleukin-18 (IL18).
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur study was aimed to established imaging models that can predict the prognosis of breast cancer patients based on IL18, so as to facilitate the formulation of more individualized treatment plans during the treatment.
methodWe established enhancing MRI models to predict the mRNA expression of IL18 in breast cancer tissues. Meanwhile, bioinformatics analysis was integrated to studied the expression of IL18 in breast cancer with its clinical significance to explore the potential molecular mechanisms and its association with the immune microenvironment.
resultIn breast cancer patients, high levels of IL18 expression are associated with improved overall survival (OS), and natural killer cells (NK cells) significantly increased (P < 0.001) with elevated IL18. Three radiomics models, RFE-GBM, Relief-GBM, and RFE_Relief-GBM were established in our study, each model demonstrated strong predictive consistency in the prognosis of breast cancer patients.
conclusionIL18 is a protective factor in breast cancer, our radiomics models can serve as valuable non-invasive tools for utilizing mRNA expression of IL18 by enhancing MRI and show promise in predicting prognosis of breast cancer patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.